Clinical Trial

Clemastine Treatment in Individuals With Williams Syndrome

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-11; most recent amendment 2026-03-04.
Status change: Recruiting → Active, Not Recruiting 2026-03-04
Trial Details
NCT Number NCT06087757
Lead Sponsor Sheba Medical Center
Collaborators: Tel Aviv University
Conditions Williams Syndrome
Enrollment 30 participants
Start Date 2024-04-01
Primary Completion 2026-05 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-06